Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.77M | 1.50M | 1.18M | 984.20K | 872.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.77M | 1.50M | 1.18M | 984.20K | 872.50K |
| Cost of Revenue | 823.60K | 649.90K | 475.20K | 383.50K | 328.30K |
| Gross Profit | 941.70K | 851.50K | 702.40K | 600.70K | 544.20K |
| SG&A Expenses | 3.32M | 3.57M | 3.04M | 2.67M | 2.28M |
| Depreciation & Amortization | 208.60K | 174.10K | 286.70K | 363.60K | 432.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.43M | 4.50M | 4.10M | 3.75M | 3.37M |
| Operating Income | -2.66M | -3.00M | -2.93M | -2.77M | -2.50M |
| Income Before Tax | -3.48M | -3.89M | -4.25M | -3.97M | -3.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.48 | -3.89 | -4.25 | -3.97 | -3.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.48M | -3.89M | -4.25M | -3.97M | -3.72M |
| EBIT | -2.66M | -3.00M | -2.93M | -2.77M | -2.50M |
| EBITDA | -2.54M | -2.86M | -2.73M | -2.50M | -2.15M |
| EPS Basic | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 504.43M | 494.81M | 478.84M | 458.02M | 438.48M |
| Average Diluted Shares Outstanding | 504.43M | 494.81M | 478.84M | 458.02M | 438.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |